Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice

D. F. Carmichael, G. P. Stricklin, John Stuart

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.

Original languageEnglish (US)
Pages (from-to)378-379
Number of pages2
JournalAgents and Actions
Volume27
Issue number3-4
DOIs
StatePublished - Jun 1 1989

Fingerprint

Experimental Arthritis
Collagen Type II
Metalloproteases
Collagen
Tissue
Inbred DBA Mouse
Pathology
Erosion
Joints
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology (medical)

Cite this

Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. / Carmichael, D. F.; Stricklin, G. P.; Stuart, John.

In: Agents and Actions, Vol. 27, No. 3-4, 01.06.1989, p. 378-379.

Research output: Contribution to journalArticle

Carmichael, D. F. ; Stricklin, G. P. ; Stuart, John. / Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice. In: Agents and Actions. 1989 ; Vol. 27, No. 3-4. pp. 378-379.
@article{6dfc6f90e451424b9456d9665443cd4a,
title = "Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice",
abstract = "The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.",
author = "Carmichael, {D. F.} and Stricklin, {G. P.} and John Stuart",
year = "1989",
month = "6",
day = "1",
doi = "10.1007/BF01972827",
language = "English (US)",
volume = "27",
pages = "378--379",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "3-4",

}

TY - JOUR

T1 - Systemic administration of TIMP in the treatment of collagen-induced arthritis in mice

AU - Carmichael, D. F.

AU - Stricklin, G. P.

AU - Stuart, John

PY - 1989/6/1

Y1 - 1989/6/1

N2 - The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.

AB - The type II collagen induced arthritis model was used to evaluate the efficacy of tissue inhibitor of metalloproteases (TIMP) in suppressing the disease in DBA/1 mice. Treatment began following the first clinical manifestations of the disease state. Clinical observations, histological and radiographic findings show a decreased incidence of joint erosion in the treated population relative to the controls. It is concluded that systemic administration of recombinant human TIMP suppresses the pathology of type II collagen induced arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0024337629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024337629&partnerID=8YFLogxK

U2 - 10.1007/BF01972827

DO - 10.1007/BF01972827

M3 - Article

VL - 27

SP - 378

EP - 379

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 3-4

ER -